NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Descending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70954-0566-20 | 70954-0566 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70954-0564-10 | 70954-0564 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70518-3401-07 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 6, 2023 | In Use | |
71205-0797-15 | 71205-0797 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 5, 2023 | In Use | |
70860-0228-61 | 70860-0228 | Melphalan hydrochloride | Melphalan Hydrochloride | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sept. 1, 2023 | In Use | |
72189-0511-10 | 72189-0511 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 1, 2023 | In Use | |
82009-0086-90 | 82009-0086 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2023 | In Use | |
82009-0087-30 | 82009-0087 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2023 | In Use | |
68001-0545-41 | 68001-0545 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2023 | In Use | |
68001-0546-41 | 68001-0546 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2023 | In Use |
Found 10,000 results in 3 milliseconds — Export these results